Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.

[1]  T. Ganz,et al.  Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. , 2008, Molecular immunology.

[2]  J. Cigudosa,et al.  Expression signatures in lung cancer reveal a profile for EGFR‐mutant tumours and identify selective PIK3CA overexpression by gene amplification , 2008, The Journal of pathology.

[3]  E. C. Xu,et al.  Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. , 2007, Cancer letters.

[4]  H. Dienemann,et al.  Molecular determinants of response to RTK‐targeting agents in nonsmall cell lung cancer , 2006, International journal of cancer.

[5]  Kenji Suzuki,et al.  Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma , 2006, International journal of cancer.

[6]  J. D'haese,et al.  Chromosomal aberrations in follicular non-Hodgkin lymphomas of Japanese patients, detected with comparative genomic hybridization and polymerase chain reaction analysis. , 2005, Cancer genetics and cytogenetics.

[7]  J. Minna,et al.  Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. , 2005, Human pathology.

[8]  B. Brandt,et al.  Cytogenetic differences in breast cancer samples between German and Japanese patients , 2005, Journal of Clinical Pathology.

[9]  S. Hirohashi,et al.  Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features , 2005, Clinical Cancer Research.

[10]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[11]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[12]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[13]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[14]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[15]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Hiroyuki Sakurai,et al.  Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas , 2005, Cancer.

[17]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[20]  Michael Peyton,et al.  Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.

[21]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[22]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[23]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[24]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Sliwkowski,et al.  Preclinical studies with Erlotinib (Tarceva). , 2003, Seminars in oncology.

[26]  L. Ellis,et al.  Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells , 2003, British Journal of Cancer.

[27]  F. Hirsch,et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.

[28]  S. Petersen,et al.  Chromosomal imbalances of primary and metastatic lung adenocarcinomas , 2002, The Journal of pathology.

[29]  Thomas Ragg,et al.  Bayesian learning and evolutionary parameter optimization , 2001, AI Commun..

[30]  A. Harris,et al.  Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway , 2001, British Journal of Cancer.

[31]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[32]  N. Reinmuth,et al.  Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. , 2000, The European respiratory journal.

[33]  L. Ellis,et al.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases , 2000, Cancer.

[34]  S. Scholnick,et al.  Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p , 1999, Oncogene.

[35]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[36]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[37]  Thomas Cremer,et al.  Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization , 1993, Human Genetics.

[38]  K. Kinzler,et al.  Relationship between gene amplification and chromosomal deviations in malignant human gliomas. , 1987, Cancer genetics and cytogenetics.

[39]  Y. Shimosato,et al.  Histological Typing of Lung Tumours 1 , 1981 .

[40]  BMC Molecular Biology BioMed Central , 2008 .

[41]  N. Reinmuth,et al.  Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. , 2007, Lung cancer.